Literature DB >> 31502411

Subependymal giant cell astrocytoma harboring a PRRC2B-ALK fusion: A case report.

Takao Tsurubuchi1, Yoshiko Nakano2, Junko Hirato3, Akihiko Yoshida4, Ai Muroi1, Noriaki Sakamoto1, Zaboronok Alexander1, Masahide Matsuda1, Eiichi Ishikawa1, Takashi Kohno5, Takako Yoshioka6, Mai Honda-Kitahara2, Koichi Ichimura2, Tetsuya Yamamoto1,7, Akira Matsumura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31502411     DOI： 10.1002/pbc.27995

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  2 in total

1.  Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report.

Authors:  Zhan Wang; Yan Geng; Ling-Yan Yuan; Miao-Miao Wang; Chen-Yang Ye; Li Sun; Wei-Ping Dai; Yuan-Sheng Zang
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

2.  Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile.

Authors:  Krinio Giannikou; Zachary Zhu; Jaegil Kim; Kellen D Winden; Magdalena E Tyburczy; David Marron; Joel S Parker; Zachary Hebert; Anika Bongaarts; Len Taing; Henry W Long; William V Pisano; Sanda Alexandrescu; Brianna Godlewski; Mark Nellist; Katarzyna Kotulska; Sergiusz Jozwiak; Marcin Roszkowski; Marek Mandera; Elizabeth A Thiele; Hart Lidov; Gad Getz; Orrin Devinsky; Michael S Lawrence; Keith L Ligon; David W Ellison; Mustafa Sahin; Eleonora Aronica; David M Meredith; David J Kwiatkowski
Journal:  Mod Pathol       Date:  2020-10-13       Impact factor: 8.209
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.